Cancer BiologybioRxivPreprint
Targeting CXCR1 and CXCR2 to overcome radiotherapy resistance in PTEN-deficient prostate carcinoma
C. W. D. Armstrong, J. A. Coulter, C. W. Ong…·D. J. J. Waugh
This study identifies PTEN-deficiency-associated CXC-chemokine signaling as a driver of radiotherapy resistance in prostate cancer and shows that targeting CXCR1/2 improves radiotherapy outcomes.
DOI 10.1101/2020.03.16.993394